Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Revenue (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Revenue for 7 consecutive years, with $7.1 million as the latest value for Q1 2025.

  • Quarterly Revenue rose 33.48% to $7.1 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, down 72.5% year-over-year, with the annual reading at $7.1 million for FY2025, 72.5% down from the prior year.
  • Revenue for Q1 2025 was $7.1 million at Whitehawk Therapeutics, down from $7.2 million in the prior quarter.
  • The five-year high for Revenue was $14.0 million in Q4 2021, with the low at $120000.0 in Q1 2021.
  • Average Revenue over 5 years is $5.8 million, with a median of $6.0 million recorded in 2023.
  • Peak annual rise in Revenue hit 1822.5% in 2022, while the deepest fall reached 62.66% in 2022.
  • Over 5 years, Revenue stood at $14.0 million in 2021, then crashed by 62.66% to $5.2 million in 2022, then grew by 21.03% to $6.3 million in 2023, then rose by 14.43% to $7.2 million in 2024, then dropped by 1.3% to $7.1 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $7.1 million, $7.2 million, and $7.2 million for Q1 2025, Q4 2024, and Q3 2024 respectively.